- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | Coiled Therapeutics - Investor Presentation via Engage Investor | - | RNS | ||
| 30.09. | Coiled Therapeutics - Participation in The Small Cap Showcase | - | RNS | ||
| 28.09. | Coiled Therapeutics - Director/PDMR Shareholding | - | RNS | ||
| 28.09. | Coiled Therapeutics - Interim Results to 30 June 2026 | - | RNS | ||
| COILED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.09. | IN BRIEF: Coiled Therapeutics progresses AO-252 testing enrolment | 4 | Alliance News | ||
| 21.09. | Coiled Therapeutics completes enrollment in AO-252 trial cohorts | 2 | Investing.com | ||
| 21.09. | Coiled Therapeutics: Rekrutierung für neue AO-252-Formulierung abgeschlossen | 1 | Investing.com Deutsch | ||
| 21.09. | Coiled Therapeutics - Successful Enrolment Completed Across Two Cohorts | - | RNS | ||
| 01.09. | Coiled Therapeutics - Appointment of Joint Corporate Broker | - | RNS | ||
| 03.08. | Coiled Therapeutics - First Patient Dosed with new Formulation of AO-252 | - | RNS | ||
| 07.07. | Coiled Therapeutics develops new formulation for AO-252 | 1 | Investing.com | ||
| 07.07. | Coiled Therapeutics - Coiled Advances Next-Generation AO-252 Formulation | - | RNS | ||
| 24.06. | Coiled Therapeutics - Company Presentation | - | RNS | ||
| 24.06. | Coiled Therapeutics - Result of AGM | - | RNS | ||
| 24.06. | Coiled Therapeutics - Appointment of Independent Non-Executive Director | - | RNS | ||
| 19.06. | Coiled Therapeutics - Life Sciences Investor Forum | - | RNS | ||
| 18.06. | Coiled Therapeutics - Proactive One2One Investor Forum | - | RNS | ||
| 17.06. | Coiled Therapeutics - Grant of Share Options | 1 | RNS | ||
| 17.06. | Coiled Therapeutics beruft renommierte Onkologen in medizinischen Beirat | - | Investing.com Deutsch | ||
| 17.06. | Coiled Therapeutics establishes medical advisory board | 1 | Investing.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,050 | +0,26 % | EQT lässt für Qiagen 9,6 Milliarden Euro springen | Der schwedische Private-Equity-Investor EQT übernimmt den europäische Molekulardiagnostik-Spezialisten Qiagen. Mit 9,6 Mrd. Euro ist die Transaktion eine der größten Übernahmen im europäischen Gesundheitssektor... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,990 | -11,08 % | Wedbush raises Tango Therapeutics stock price target on trial data | ||
| MODERNA | 179,18 | -0,84 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| BOLT BIOTHERAPEUTICS | 6,810 | +67,73 % | Bolt Biotherapeutics, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 15,370 | -1,16 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,645 | +0,14 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast | ||
| DISC MEDICINE | 74,36 | -0,95 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| HARMONY BIOSCIENCES | 35,130 | -2,50 % | Harmony Biosciences: Mizuho bekräftigt Einstufung nach Verhandlungen im Patentrechtsstreit | ||
| NAUTILUS BIOTECHNOLOGY | 3,160 | +16,61 % | Nautilus Biotechnology Inc.: Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 | ||
| PRAXIS PRECISION MEDICINES | 252,04 | -1,73 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 50,59 | -3,78 % | Biotech Stocks At 52-Week Highs - Bioventus, Travere Therapeutics, Odyssey Therapeutics, Charles River Laboratories Climb With Q2 Results, Aclaris Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.Bioventus Inc. (BVS)Bioventus is a medical device... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,725 | -3,32 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| NURIX THERAPEUTICS | 25,110 | -1,57 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| BIONTECH | 78,90 | -1,31 % | BioNTech-Aktie: Was die Gilead-Allianz jetzt verändert | ||
| ERASCA | 14,100 | -2,69 % | Erasca drops after sacking COO |
COILED THERAPEUTICS PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +4,98 % bei einem Aktienkurs von 0,065 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COILED THERAPEUTICS PLC finden Sie auf Wallstreet Online.